Bimekizumab治疗中重度斑块状银屑病3年疗效与安全性:BE RADIANT IIIb期开放标签扩展结果
BE RADIANT IIIb期试验开放标签扩展显示,随机接受bimekizumab治疗的患者第1年PASI 100应答率(74.9%)高于随机接受secukinumab者(52.8%),3年时两组PASI 100应答率均为68.8%。Bimekizumab耐受性良好,3年内最常见治疗中出现的不良事件为鼻咽炎、口腔念珠菌感染和上呼吸道感染,暴露调整发生率分别为12.2、10.0和5.5/100患者年,关注的不良事件率未随暴露时间延长而增加。
要点
- Bimekizumab治疗3年可使约三分之二患者维持PASI 100应答。
- 从secukinumab切换至bimekizumab后PASI 100应答率提高至68.8%。
- 3年内最常见不良事件为鼻咽炎、口腔念珠菌感染和上呼吸道感染。
核心结论
- 超过三分之二随机接受bimekizumab及从secukinumab切换至bimekizumab的患者在3年治疗期间达到并维持完全皮损清除。
- Bimekizumab耐受性良好,治疗中出现的不良事件率未随暴露时间延长而增加。
研究设计与样本
- BE RADIANT IIIb期随机对照试验,含48周双盲期及后续开放标签扩展期。
- 双盲期患者随机接受bimekizumab 320 mg每4周或secukinumab 300 mg(第0-4周每周,之后每4周)。
- 第16周时bimekizumab组重新随机分为每4周或每8周维持给药。
- 第48周起开放标签扩展期所有患者均接受bimekizumab。
- 基线随机至bimekizumab组336例、secukinumab组318例进入开放标签扩展期。
主要发现
- 第1年时随机接受bimekizumab组PASI 100应答率(改良无应答者填补)为74.9%,随机接受secukinumab组为52.8%。
- 3年时bimekizumab持续治疗组PASI 100应答率为68.8%,随机接受secukinumab后切换至bimekizumab组亦为68.8%。
- 接受至少1剂bimekizumab的患者中,3年内最常见治疗中出现的不良事件为鼻咽炎、口腔念珠菌感染和上呼吸道感染,暴露调整发生率分别为12.2、10.0和5.5/100患者年。
- 从第1年至第3年,包括严重感染、炎症性肠病和自杀意念及行为在内的关注的不良事件率未随bimekizumab暴露延长而增加。
临床怎么用
- 对于中重度斑块状银屑病患者,bimekizumab可持续维持完全皮损清除达3年。
- 从secukinumab切换至bimekizumab可改善并维持临床应答。
- 长期使用bimekizumab时需关注鼻咽炎、口腔念珠菌感染和上呼吸道感染等常见不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Overexpression of interleukin (IL)-17A and IL-17F significantly influences psoriasis pathology. Until recently, biologics targeting IL-17A alone, like secukinumab, were used to treat psoriasis. Bimekizumab is a monoclonal IgG1 antibody that targets both IL-17A and IL-17F. BE RADIANT was the first phase III trial to investigate switching from selective inhibition of IL-17A to dual inhibition of IL-17A and IL-17F. Bimekizumab has previously shown superior achievement of complete skin clearance [100% improvement from baseline in Psoriasis Area and Severity Index (PASI 100)] vs. secukinumab through 48 weeks. Switching from secukinumab to bimekizumab resulted in improved clinical responses. Over 2 years, no new safety signals were observed. OBJECTIVES: To report the 3-year efficacy and safety of bimekizumab in patients with moderate-to-severe plaque psoriasis receiving continuous bimekizumab or switching from secukinumab after 1 year. METHODS: The BE RADIANT phase IIIb randomized controlled trial had a 48-week double-blinded period, in which patients received bimekizumab [320 mg every 4 weeks (Q4W)] or secukinumab (300 mg weekly to week 4, then Q4W). At week 16, patients randomized to bimekizumab underwent re-randomization to receive Q4W or Q8W maintenance dosing. From week 48 onward (open-label extension), all received bimekizumab. RESULTS: In total, 336 patients randomized to bimekizumab and 318 randomized to secukinumab at baseline entered the open-label extension. More patients randomized to bimekizumab achieved PASI 100 (modified nonresponder imputation) at year 1 (74.9%) vs. those randomized to secukinumab (52.8%). PASI 100 response rates were maintained over 3 years in patients treated with bimekizumab (68.8%) and increased in those randomized to secukinumab switching to bimekizumab (68.8%). Bimekizumab was well tolerated to 3 years. In patients who received ≥ 1 bimekizumab dose, the most common treatment-emergent adverse events (TEAEs) over 3 years were nasopharyngitis, oral candidiasis and upper respiratory tract infection (exposure-adjusted incidence rates 12.2, 10.0 and 5.5/100 patient-years, respectively). Rates of TEAEs of interest, including serious infections, inflammatory bowel disease, and suicidal ideation and behaviour, did not increase with longer exposure to bimekizumab from 1 to 3 years. CONCLUSIONS: More than two-thirds of patients randomized to bimekizumab and those who switched from secukinumab to bimekizumab achieved and maintained complete skin clearance over 3 years of treatment. Over 3 years, bimekizumab was well tolerated and TEAE rates did not increase with longer exposure. TRIAL REGISTRATION: NCT03536884. Psoriasis is a skin condition that affects around 2 in every 100 people. It causes red, scaly patches of skin that can be painful, flaky and itchy. Many people living with psoriasis want treatments to work faster, better and for longer, to achieve completely clear skin. Finding treatments that work well and have few side effects is important. Bimekizumab and secukinumab are drugs for psoriasis given by injection. A previous study showed that bimekizumab worked better than secukinumab over 1 year. We tracked patients for up to 3 years to see if bimekizumab kept working well. Some took secukinumab for the first year and then switched to bimekizumab, while others took bimekizumab the whole time. After 4 weeks, we found that more patients given bimekizumab had clear skin than those who took secukinumab. Similarly, after 1 year, more patients taking bimekizumab achieved clear skin than those taking secukinumab. Two-thirds of patients maintained clear skin over 3 years. Patients who switched from secukinumab to bimekizumab had similar results to those who took bimekizumab the whole time. Bimekizumab was well-tolerated. The number and types of side effects over 3 years were similar to those seen over 1 year. They included the common cold, oral thrush and infections of the nose, mouth and/or throat. Few side effects were serious or led to patients dropping out of the study. Our results suggest that treatment with bimekizumab can help people with psoriasis keep their skin clear for up to 3 years. This includes people who switched from secukinumab. Bimekizumab was well-tolerated and rates of side effects did not increase with the length of time it was taken for.
引用
- Warren RB, Lebwohl M, Thaçi D, et al. Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period. Br J Dermatol. 2025. PMID: 39862230. doi:10.1093/bjd/ljaf032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。